静脉溶栓对急性脑梗死并脑微出血患者近远期预后的影响被引量：9

下载PDF

导出

摘要目的探讨静脉溶栓对急性脑梗死并脑微出血患者近远期预后的影响。方法选取52例急性脑梗死合并脑微出血患者,随机分为对照组和研究组,各26例,对照组给予常规治疗,研究组在常规治疗基础上加用静脉溶栓治疗,记录两组患者治疗前、治疗2周、3个月后神经功能缺损变化情况。结果两组患者治疗前NIHSS评分差异无统计学意义(P>0.05),治疗2周后研究组NIHSS评分明显低于对照组(P<0.05)。治疗3个月后研究组mRS评分明显低于对照组(P<0.05)。结论对急性脑梗死合并脑微出血患者给予静脉溶栓治疗可显著改善其神经功能缺损情况,有利于保障患者近远期预后效果。

作者刘秀君

机构地区遂平县人民医院保健科

出处《河南医学研究》 CAS 2015年第8期75-76,共2页 Henan Medical Research

关键词急性脑梗死脑微出血静脉溶栓预后

分类号 R743 [医药卫生—神经病学与精神病学]

引文网络
相关文献

参考文献5

1唐政杰,卓成龙,李宇博,丁立祥.椎体后凸成形术后再发骨折内固定治疗失效1例治疗报告[J].中国骨与关节外科,2014,7(2):160-162. 被引量：1
2包芳,孙小力,曹桂芝.重组组织型纤溶酶原激活物静脉溶栓超早期治疗急性脑梗死疗效观察[J].中国实用神经疾病杂志,2014,17(8):86-87. 被引量：14
3郭义坤,李焰生.急性脑梗死患者重组组织型纤溶酶原激活物静脉溶栓后脑出血[J].国际脑血管病杂志,2010,18(2):113-118. 被引量：10
4王世芳,肖卫民,吴志强.急性脑梗死静脉溶栓后早期脑出血转化的相关因素分析[J].赣南医学院学报,2013,33(2):199-202. 被引量：14
5赵惠荣,元小冬,郭晶,郭庆乐,王燕玲.CT灌注成像指导重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死临床观察[J].河北联合大学学报（医学版）,2014,16(2):147-149. 被引量：12

二级参考文献68

1陈唯唯,漆剑频,肖明,宋金梅.CT灌注成像对超急性脑梗死半暗带两种判定方法的一致性研究[J].中国医学影像技术,2005,21(2):258-260. 被引量：32
2冀瑞俊,贾建平,马欣,楚长彪.“病理生理窗”指导下的溶栓干预模式探讨[J].脑与神经疾病杂志,2007,15(2):89-91. 被引量：17
3The National Institute of Netrological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischernic stroke. N Engt J Med, 1995, 333: 1581-1587.
4Hacke W, Donnan G, Fieschi C, et al.ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet, 2004, 363: 768 -774.
5Reeves MJ, Arora S, Broderick JP, et al; Paul Coverdell Prototype Registries Writing Group. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke, 2005, 36: 1232-1240.
6The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke, 1997, 28: 2109- 2118.
7Hacke W, Kaste M, Fieschi C, etal. Rardomised double-blind placebocoutrolled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS H). Second European-Australasian Acute Stroke Study Investigators. Lancet, 1998, 352: 1245-1251.
8Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral hemorrhage after intra-arterial tbrombolysis for ischemic stroke: the PROACT Ⅱ trial. Neurology, 2001,57: 1603-1610.
9Lame V, von Kummer R R, Muller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasrninogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS Ⅱ). Stroke, 2001,32: 438-441.
10Clark WM, Wissman S, Atbers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA, 1999, 282: 2019-2026.